Astellas Pharma (OTCMKTS:ALPMY) Sees Unusually-High Trading Volume – Time to Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw strong trading volume on Wednesday . 120,240 shares changed hands during trading, a decline of 19% from the previous session’s volume of 149,343 shares.The stock last traded at $16.74 and had previously closed at $16.14.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Citigroup downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Jefferies Financial Group upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Finally, Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Astellas Pharma presently has a consensus rating of “Hold”.

Astellas Pharma Trading Down 1.8%

The company has a current ratio of 1.09, a quick ratio of 0.84 and a debt-to-equity ratio of 0.23. The stock has a 50-day simple moving average of $15.47 and a 200 day simple moving average of $13.34. The company has a market cap of $29.82 billion, a price-to-earnings ratio of 13.85 and a beta of 0.17.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15. Astellas Pharma had a return on equity of 23.62% and a net margin of 15.63%.The business had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.21 billion. As a group, equities research analysts predict that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).